PE10299A1 - Procedimiento para sintetizar piridinas sustituidas - Google Patents
Procedimiento para sintetizar piridinas sustituidasInfo
- Publication number
- PE10299A1 PE10299A1 PE1997001004A PE00100497A PE10299A1 PE 10299 A1 PE10299 A1 PE 10299A1 PE 1997001004 A PE1997001004 A PE 1997001004A PE 00100497 A PE00100497 A PE 00100497A PE 10299 A1 PE10299 A1 PE 10299A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- formula
- base
- procedure
- pyridin
- Prior art date
Links
- 230000002194 synthesizing effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 11
- -1 1,2-DIHYDROXYETHYL Chemical class 0.000 abstract 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000000048 adrenergic agonist Substances 0.000 abstract 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229910000487 osmium oxide Inorganic materials 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- JIWAALDUIFCBLV-UHFFFAOYSA-N oxoosmium Chemical group [Os]=O JIWAALDUIFCBLV-UHFFFAOYSA-N 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE AL PROCEDIMIENTO DE PREPARACION DEL COMPUESTO DE FORMULA (I) Y DE LOS COMPUESTOS INTERMEDIOS DE FORMULA (II) Y (VI), QUE COMPRENDE: HACER REACCIONAR UN COMPUESTO DE FORMULA (V) CON UN CATALIZADOR QUE ES OXIDO DE OSMIO VIII Y UN AGENTE OXIDANTE AUXILIAR, EN PRESENCIA DE UN LIGANDO QUIRAL AUXILIAR Y UNA BASE AUXILIAR; EL COMPUESTO (VI) OBTENIDO, HACER REACCIONAR CON CLORURO DE ORGANOSULFONILO Y UNA BASE; EL COMPUESTO (II) OBTENIDO, HACER REACCIONAR CON UNA BASE NO NUCLEOFILICA; EL COMPUESTO OBTENIDO HACER REACCIONAR CON UNA BASE e HNY2Y3, PARA OBTENER (I). TAMBIEN SE REFIERE AL PROCEDIMIENTO DE PREPARACION DEL COMPUESTO (XIII), TAL COMO (I) EN DONDE: R1 ES NH2, "Y1" e "Y3" SON H; Y2 ES (CH2)2-O-FENILO-CH2-COOH. ADEMAS SE REFIERE A LOS COMPUESTOS INTERMEDIOS DE FORMULA (IIa) Y (VIII), EN DONDE, SON COMPUESTOS (IIa) PREFERIDOS: N-(5-(1,2-DIHIDROXIETIL)-PIRIDIN-2-IL)ACETAMIDA; N-(5-(2-CLORO-1-HIDROXIETIL)-1-PIRIDIN-2-IL)-ACETAMIDA; 2-(6-ACETILAMINO-PIRIDIN-3-IL)-2-HIDROXIETIL ESTER DEL ACIDO TOLUENO-4-SULFONICO; UN COMPUESTO (VIII) PREFERIDO ES: N-METIL-4-(2-(2-(2-ACETILAMINOPIRIDIN-5-IL)-2-(R)-HIDROXIETIL-N-TERC-BUTILOXICARBONILAMINO)-ETOXI-FENILACETAMIDA. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTAS RECEPTORES �-ADRENERGICOS, SIENDO UTILES COMO AGENTES HIPOGLUCEMICOS Y CONTRA LA OBESIDAD
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3088096P | 1996-11-14 | 1996-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE10299A1 true PE10299A1 (es) | 1999-02-10 |
Family
ID=21856496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997001004A PE10299A1 (es) | 1996-11-14 | 1997-11-11 | Procedimiento para sintetizar piridinas sustituidas |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US6291489B1 (es) |
| EP (1) | EP0938476B1 (es) |
| JP (1) | JP3510635B2 (es) |
| KR (1) | KR20000053314A (es) |
| CN (1) | CN1237160A (es) |
| AP (1) | AP805A (es) |
| AR (1) | AR010584A1 (es) |
| AT (1) | ATE319687T1 (es) |
| AU (1) | AU4634697A (es) |
| BG (1) | BG103393A (es) |
| BR (1) | BR9712951A (es) |
| CA (1) | CA2270386C (es) |
| CO (1) | CO4930261A1 (es) |
| DE (1) | DE69735433D1 (es) |
| EA (1) | EA199900375A1 (es) |
| GT (1) | GT199700118A (es) |
| HR (1) | HRP970612A2 (es) |
| ID (1) | ID18898A (es) |
| IL (1) | IL129688A0 (es) |
| IS (1) | IS5029A (es) |
| MA (1) | MA24401A1 (es) |
| MY (1) | MY132507A (es) |
| NO (1) | NO992296D0 (es) |
| OA (1) | OA11044A (es) |
| PA (1) | PA8441401A1 (es) |
| PE (1) | PE10299A1 (es) |
| TN (1) | TNSN97172A1 (es) |
| TR (1) | TR199901063T2 (es) |
| UY (1) | UY24774A1 (es) |
| WO (1) | WO1998021184A1 (es) |
| YU (1) | YU22099A (es) |
| ZA (1) | ZA9710186B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3605299A (en) * | 1998-04-08 | 1999-11-01 | Novartis Ag | Novel herbicides |
| US6090942A (en) * | 1998-10-15 | 2000-07-18 | Pfizer Inc. | Process and intermediates for a β3 -adrenergic receptor agonist |
| EP1153919A4 (en) * | 1999-02-16 | 2002-10-02 | Kaneka Corp | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 ADRENERGIC RECEPTOR AGONIST USING THE SAME |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| EP1078924B1 (en) * | 1999-07-23 | 2004-10-20 | Pfizer Products Inc. | Intermediates and a process for producing beta-adrenergic receptor agonists |
| WO2003033468A1 (fr) * | 2001-10-17 | 2003-04-24 | Kaneka Corporation | Procede de preparation de derives de (s)-$g(a)-halomethylpyridine-methanol |
| WO2003072573A1 (en) * | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol |
| US6864268B2 (en) | 2002-02-27 | 2005-03-08 | Pfizer Inc. | β3 adrenergic receptor agonists |
| MXPA04008298A (es) * | 2002-02-27 | 2004-11-26 | Pfizer Prod Inc | Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico. |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| ATE406363T1 (de) | 2003-05-09 | 2008-09-15 | Hoffmann La Roche | Methylindole und methylpyrrolopyridine als alpha- 1-adrenerge agonisten |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| CA2724726C (en) | 2008-05-23 | 2018-02-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein inhibitor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4358455A (en) | 1980-12-23 | 1982-11-09 | Merck & Co., Inc. | Aralkylamindethanol heterocyclic compounds |
| US5019578A (en) | 1987-11-27 | 1991-05-28 | Merck & Co., Inc. | β-adrenergic agonists |
| AU675536B2 (en) | 1993-06-14 | 1997-02-06 | Pfizer Inc. | Secondary amines as antidiabetic and antiobesity agents |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
| US5977124A (en) * | 1995-05-10 | 1999-11-02 | Pfizer Inc. | β-adrenergic agonists |
| CA2220538A1 (en) | 1995-05-10 | 1996-11-14 | Pfizer Inc. | .beta.-adrenergic agonists |
-
1997
- 1997-11-03 EA EA199900375A patent/EA199900375A1/ru unknown
- 1997-11-03 WO PCT/IB1997/001367 patent/WO1998021184A1/en active IP Right Grant
- 1997-11-03 US US09/297,694 patent/US6291489B1/en not_active Expired - Fee Related
- 1997-11-03 EP EP97945047A patent/EP0938476B1/en not_active Expired - Lifetime
- 1997-11-03 TR TR1999/01063T patent/TR199901063T2/xx unknown
- 1997-11-03 JP JP52233298A patent/JP3510635B2/ja not_active Expired - Fee Related
- 1997-11-03 AT AT97945047T patent/ATE319687T1/de not_active IP Right Cessation
- 1997-11-03 DE DE69735433T patent/DE69735433D1/de not_active Expired - Lifetime
- 1997-11-03 BR BR9712951-8A patent/BR9712951A/pt not_active Application Discontinuation
- 1997-11-03 CN CN97199663A patent/CN1237160A/zh active Pending
- 1997-11-03 IL IL12968897A patent/IL129688A0/xx unknown
- 1997-11-03 YU YU22099A patent/YU22099A/sh unknown
- 1997-11-03 CA CA002270386A patent/CA2270386C/en not_active Expired - Fee Related
- 1997-11-03 KR KR1019990704312A patent/KR20000053314A/ko active IP Right Grant
- 1997-11-03 AU AU46346/97A patent/AU4634697A/en not_active Abandoned
- 1997-11-11 PE PE1997001004A patent/PE10299A1/es not_active Application Discontinuation
- 1997-11-11 MA MA24864A patent/MA24401A1/fr unknown
- 1997-11-11 GT GT199700118A patent/GT199700118A/es unknown
- 1997-11-12 MY MYPI97005396A patent/MY132507A/en unknown
- 1997-11-12 ZA ZA9710186A patent/ZA9710186B/xx unknown
- 1997-11-12 UY UY24774A patent/UY24774A1/es unknown
- 1997-11-12 PA PA19978441401A patent/PA8441401A1/es unknown
- 1997-11-12 TN TNTNSN97172A patent/TNSN97172A1/fr unknown
- 1997-11-12 AR ARP970105279A patent/AR010584A1/es not_active Application Discontinuation
- 1997-11-13 AP APAP/P/1997/001147A patent/AP805A/en active
- 1997-11-13 ID IDP973662A patent/ID18898A/id unknown
- 1997-11-13 HR HR60/030,880A patent/HRP970612A2/hr not_active Application Discontinuation
- 1997-11-13 CO CO97066763A patent/CO4930261A1/es unknown
-
1999
- 1999-04-16 IS IS5029A patent/IS5029A/is unknown
- 1999-05-07 OA OA9900096A patent/OA11044A/en unknown
- 1999-05-11 BG BG103393A patent/BG103393A/xx unknown
- 1999-05-12 NO NO992296A patent/NO992296D0/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE10299A1 (es) | Procedimiento para sintetizar piridinas sustituidas | |
| PE20000726A1 (es) | Derivados terapeuticos de biarilo | |
| DK1445258T3 (da) | Aktivator for peroxisomproliferator-aktiveret receptor delta | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| CO4990955A1 (es) | Derivados de n-alcanoilofenilalanina | |
| BRPI0212775B8 (pt) | composto de 1,2,4-triazol e medicamento | |
| KR920700202A (ko) | 아크릴로일 치환된 피롤 유도체 | |
| PE20001483A1 (es) | Acidos oxamicos y derivados como ligandos de receptores tiroideos | |
| CO4990936A1 (es) | Derivados de n-aroilfenilalanina | |
| PE20021072A1 (es) | DERIVADOS DE DIHIDRO-BENZO(b) (1,4)-DIAZEPIN-2-ONA COMO ANTAGONISTAS I DE mGLUR2 | |
| KR960705780A (ko) | 평활근 이완제로서의 디아미노사이클로부텐-3.4-디온(Diaminocyclobutene-3.4-diones as smooth muscle relaxants) | |
| PE20070007A1 (es) | Metodos para sintetizar derivados de 6-alquilaminoquinolina | |
| PE20040672A1 (es) | Derivados de fenil o heteroaril amino alcano | |
| KR960702460A (ko) | 티아졸리딘디온 및 이것을 함유하는 약제(new thiazolidindiones and drugs containing them) | |
| CA2444244A1 (en) | Methods of synthesizing acylanilides including bicalutamide and derivatives thereof | |
| PE20040520A1 (es) | Derivados de n-acilamino bencil eter | |
| KR950701321A (ko) | 신규의 치환된 3급 아미노 화합물의 또는 이의 염(Novel substituted tertiary amino compound or salt thereof) | |
| DE60007745D1 (de) | Heterocyclische aminopyrrolidon-derivate als melatonergene wirkstoffe | |
| PE20030539A1 (es) | Derivados de piperazina antagonistas de los receptores de somatostatina sst1 | |
| PE20010954A1 (es) | Bencimidazoles, su preparacion y su empleo como medicamentos | |
| PE20001332A1 (es) | Derivados n-fenil-n`-fenilpropilpiperazina y un metodo para su produccion | |
| KR940005540A (ko) | 카르복시산 유도체 | |
| PE20000725A1 (es) | Compuestos de alcoxipirrolidinona como inhibidores de proteasas | |
| GB0003257D0 (en) | Heterocyclic compounds and their therapeutic use | |
| EA200100783A1 (ru) | Соединения - агонисты дофаминовых рецепторов d1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |